CCT3 has been involved in mitosis progression and associated with poor prognosis in hepatocellular carcinoma [33], has been implicated in osteosarcoma tumorigenesis [34], and appeared as a candidate biomarker in epithelial ovarian cancer [35] and in cholangiocarcinoma patients [36]. This evidence concerns the gene CCT3 and osteosarcoma.